Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 11
Submit an article Journal homepage
139
Views
6
CrossRef citations to date
0
Altmetric
Reviews

The evolution of biomarkers in rheumatoid arthritis: From clinical research to clinical care

Theodorus van den Broek University of Arizona, Arizona Arthritis Center, 1501 N. Campbell Avenue, Rm 8301, PO Box 245093, Tucson, Arizona 85724-5093, USA +1 520 626 5026; +1 520 626 5018; [email protected]
, MD,
John RP Tesser University of Arizona, Arizona Arthritis Center, 1501 N. Campbell Avenue, Rm 8301, PO Box 245093, Tucson, Arizona 85724-5093, USA +1 520 626 5026; +1 520 626 5018; [email protected]; Arizona Arthritis & Rheumatology Associates, P.C. 10599 N. Tatum Blvd., Suite F-150, Paradise Valley, Arizona 85253, USA
, MD FACP FACR &
Salvatore Albani University of Arizona, Arizona Arthritis Center, 1501 N. Campbell Avenue, Rm 8301, PO Box 245093, Tucson, Arizona 85724-5093, USA +1 520 626 5026; +1 520 626 5018; [email protected]; EUREKA Institute for Translational Medicine
, MD PhD
Pages 1773-1785 | Published online: 10 Oct 2008

Bibliography

  • Wolfe AM, Kellgren JH, Masi AT. The epidemiology of rheumatoid arthritis: a review. II. Incidence and diagnostic criteria. Bull Rheum Dis 1968;19(3):524-9
  • Scott DL, Symmons DP, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1(8542):1108-11
  • O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334(20):1287-91
  • Gerards AH, Landewe RB, Prins AP, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 2003;62(4):291-6
  • Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350(9074):309-18
  • Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1):26-37
  • Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363(9410):675-81
  • St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50(11):3432-43
  • Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364(9430):263-9
  • Makinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34(2):316-21
  • Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353(9164):1568-73
  • Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66(11):1443-9
  • Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006;24(6 Suppl 43):S-77-82
  • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146(6):406-15
  • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52(11):3381-90
  • Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65(6):820-2
  • Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl 2007;80:25-33
  • Prince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 2005;10(Suppl 1):S44-9
  • Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, et al. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60(10):924-7
  • Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47(8):648-53
  • van der Heide A, Remme CA, Hofman DM, et al. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38(10):1466-74
  • van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31(8):519-25
  • Combe B, Dougados M, Goupille P, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001;44(8):1736-43
  • Landewe R. Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl 2007;80:8-15
  • Hakkinen A, Kautiainen H, Hannonen P, et al. Pain and joint mobility explain individual subdimensions of the health assessment questionnaire (HAQ) disability index in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64(1):59-63
  • Leeb BF, Andel I, Sautner J, et al. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford) 2004;43(12):1504-7
  • Makinen H, Kautiainen H, Hannonen P, et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64(10):1410-3
  • Gardiner PV, Bell AL, Taggart AJ, et al. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis. Ann Rheum Dis 2005;64(3):506-7
  • Landewe R, van der Heide D, Voskuyl A, et al. Condensed 28-joint counts jeopardise the construct validity of DAS28-remission: a comparison with the original DAS. Arthritis Rheum 2004;50(Suppl):s547
  • van Riel PL, Fransen J. Established rheumatoid arthritis: clinical assessments. Best Pract Res Clin Rheumatol 2007;21(5):807-25
  • Scott DL, Houssien DA. Joint assessment in rheumatoid arthritis. Br J Rheumatol 1996;35(Suppl 2):14-8
  • De Zordo T, Mlekusch SP, Feuchtner GM, et al. Value of contrast-enhanced ultrasound in rheumatoid arthritis. Eur J Radiol 2007;64(2):222-30
  • Sharp JT. Radiologic assessment as an outcome measure in rheumatoid arthritis. Arthritis Rheum 1989;32(2):221-9
  • Genant HK, Jiang Y, Peterfy C, et al. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41(9):1583-90
  • Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001;60(9):817-27
  • Ostergaard M, Ejbjerg B, Szkudlarek M. Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography. Best Pract Res Clin Rheumatol 2005;19(1):91-116
  • Dohn UM, Ejbjerg BJ, Court-Payen M, et al. Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther 2006;8(4):R110
  • Ostergaard M, Edmonds J, McQueen F, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 2005;64(Suppl 1):i3-7
  • Tesser J, Ballehr L, Jay R, et al. MRI RAMRIS Scores in rheumatoid arthritis: experience in a large community based rheumatology practice. Arthritis Rheum 2007;56(Suppl 9):S653
  • Hameed B, Pilcher J, Heron C, et al. The relation between composite ultrasound measures and the DAS28 score, its components and acute phase markers in adult RA. Rheumatology (Oxford) 2008;47(4):476-80
  • Ballara S, Taylor PC, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001;44(9):2055-64
  • Ostergaard M, Hansen M, Stoltenberg M, et al. Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum 1999;42(5):918-29
  • Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19(1):55-72
  • Wagner U, Kaltenhauser S, Sauer H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40(2):341-51
  • van Zeben D, Hazes JM, Zwinderman AH, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991;34(7):822-30
  • Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004;75(2):330-7
  • Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005;37(12):1317-9
  • Okada Y. Proteinases and matrix degeneration. In: Harris EDBR, Firestein GS, et al. editors, Kelly's textbook of rheumatology. 7th edition. Philadelphia: Elsevier Sanders; 2005;63081:41-53
  • Mattey DL, Nixon NB, Dawes PT, et al. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun 2004;5(2):147-9
  • Tsukahara S, Shinozaki M, Ikari K, et al. Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients. Rheumatology (Oxford) 2008;47(1):41-4
  • Constantin A, Lauwers-Cances V, Navaux F, et al. Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis Rheum 2002;46(7):1754-62
  • Kurreeman FA, Padyukov L, Marques RB, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 2007;4(9):e278. Published online 18 September 2007, doi:10.1371/journal.pmed.0040278
  • Kurki P, Aho K, Palosuo T, Heliövaara M. Immunopathology of rheumatoid arthritis: antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35:914-7
  • Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position -308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48(7):1849-52
  • Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24
  • van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62(12):1195-8
  • Chen PP, Fong S, Carson DA. Rheumatoid factor. Rheum Dis Clin North Am 1987;13(3):545-68
  • Aho K, Palusuo T, Kurki P. Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum 1994;23(6):379-87
  • Barland P, Lipstein E. Selection and use of laboratory tests in the rheumatic diseases. Am J Med 1996;100(2A):S16-23
  • Egeland T, Munthe E. The role of the laboratory in rheumatology. Rheumatoid factors. Clin Rheum Dis 1983;9(1):135-60
  • Valdimarsson H, Jonsson T. Predictive value of rheumatoid factor isotypes for radiological progression in patients with rheumatoid arthritis. Scand J Rheumatol 1996;25(3):189-90
  • Emery P. The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol 1997;24(7):1436-42
  • Nakamura RM. Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis. J Clin Lab Anal 2000;14(6):305-13
  • Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M. Anti-keratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992;51:743-6
  • Westgeest AAA, Boerbooms AMTH, Jongmans M, et al. Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 1987;14:893-7
  • Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9
  • Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6
  • Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62(2):120-6
  • Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63(10):1218-21
  • De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64(2):299-302
  • Chen HA, Lin KC, Chen CH, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(1):35-9
  • Atzeni F, Sarzi-Puttini P, Dell' Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006;8(1):R3
  • Goronzy JJ, Matteson EL, Fulbright JW, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004;50(1):43-54
  • Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994;24(2):91-104
  • van Leeuwen MA, van Rijswijk MH, van der Heijde DM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993;32(Suppl 3):9-13
  • Franz J, Welsing P, de Keijzer R, et al. Disease activity scores using C-reactive protein: CRP may replace ESR in the assessment of RA disease activity. Ann Rheum Dis 2004;62(Suppl 1):151
  • Talstad I, Scheie P, Dalen H, et al. Influence of plasma proteins on erythrocyte morphology and sedimentation. Scand J Haematol 1983;31(5):478-84
  • Kushner I. C-reactive protein in rheumatology. Arthritis Rheum 1991;34(8):1065-8
  • Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163(3):1521-8
  • Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63(5):321-9
  • Berntzen HB, Munthe E, Fagerhol MK. The major leukocyte protein L1 as an indicator of inflammatory joint disease. Scand J Rheumatol Suppl 1988;76:251-6
  • Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994;21(4):733-8
  • Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007;66(8):1093-7
  • Lacki JK, Samborski W, Mackiewicz S, et al. Do changes in clinical improvement in rheumatoid arthritis patients treated with immunosuppressive drugs reflect the changes in acute phase proteins? Ups J Med Sci 1995;100(3):233-42
  • Garnero P, Landewe R, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46(11):2847-56
  • Landewe R, Geusens P, Boers M, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50(5):1390-9
  • Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999;26(2):251-8
  • Young-Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007;56(10):3236-47
  • Christgau SCP. Cartilage degradation products as markers for evaluation of patients with rheumatic disease. Clin Appl Immunol Rev 2004;4:277-94
  • Shinozaki M, Inoue E, Nakajima A, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 2007;17(5):403-8
  • Poole AR, Dieppe P. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum 1994;23(6 Suppl 2):17-31
  • Skoumal M, Kolarz G, Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol 2003;32(3):156-61
  • Roux-Lombard P, Eberhardt K, Saxne T, et al. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) 2001;40(5):544-51
  • Fex E, Eberhardt K, Saxne T. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Br J Rheumatol 1997;36(11):1161-5
  • Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64(2):196-201
  • Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-602
  • Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397(6717):315-23
  • Geusens PP, Landewe RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006;54(6):1772-7
  • Mansson B, Geborek P, Saxne T. Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction. Ann Rheum Dis 1997;56(2):91-6
  • Emery P, McInnes IB, van Vollenhoven R, et al. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47(4):392-8
  • Ehrenstein MR, Mauri C. If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. J Exp Med 2007;204(10):2249-52
  • Shevach EM. Regulatory T cells in autoimmmunity. Ann Rev Immunol 2000;18:423-49
  • Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004;22:531-62
  • Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2(9):816-22
  • Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50
  • Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005;206:232-59
  • Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004;200(3):277-85
  • Londei M. Role of regulatory T cells in experimental arthritis and implications for clinical use. Arthritis Res Ther 2005;7(3):118-20
  • Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 2007;204(1):33-9
  • Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108(1):253-61
  • Cao D, Malmstrom V, Baecher-Allan C, et al. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003;33(1):215-23
  • Cao D, van Vollenhoven R, Klareskog L, et al. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004;6(4):R335-46
  • de Kleer IM, Wedderburn LR, Taams LS, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004;172(10):6435-43
  • van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004;50(9):2775-85
  • van Amelsfort JMR, van Roon JAG, Noordegraaf M, et al. Proinflammatory mediator–induced reversal of CD4+,CD25+ regulator y T cell–mediated suppression in rheumatoid arthritis. Arthritis Rheum 2007;56(3):732-42
  • Wang J, Ioan-Facsinay A, van der Voort EI, et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007;37(1):129-38
  • Shevach EM, DiPaolo RA, Andersson J, et al. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 2006;212:60-73
  • van Broek T, Keogh E, van Wijk F, et al. Susceptibility to epitope specific immunotherapy of rheumatoid arthritis relies on the expression of co-stimulatory molecules associated with T Cell anergy and tolerance. FOCIS poster presentation; 2008
  • Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56(1):13-20
  • Valesini G, Iannuccelli C, Marocchi E, et al. Biological and clinical effects of anti-TNFα treatment. Autoimmun Rev 2007;7(1):35-41
  • Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50(5):1412-9
  • Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66(2):228-34
  • CASE JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1. the older drugs. Am J Ther 2001;8(2):123-43
  • Nestorov I, Munafo A, Papasouliotis O, et al. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol 2008;48(4):406-17
  • Manadan AM, Block JA. Rheumatoid arthritis: beyond tumor necrosis factor-α antagonists, B cell depletion, and T cell blockade. Am J Ther 2008;15(1):53-8
  • Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353(11):1114-23
  • Tsokos GC. B cells, be gone–B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med 2004;350(25):2546-8
  • Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 2007;19(3):246-51
  • Madhok R, Crilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52(3):232-4
  • Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5(4):601-6
  • Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis. Clin Rheumatol 2006;25(4):448-52

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.